The work is a bit self serving. Some are going to jump off and take some profits on the way up. The MMs will play their games in order to accumulate shares. If people don't jump off then MM will let it ride. If shareholders truly understand the value of what they are sitting on, they will let it climb to a decent level before taking profits.
In answer to the R/S, if they don't find a partner who will give them a fair deal, I see them initiating a R/S followed by an offering to raise capital to make the run for an NDA. If they are going to manufacture Libigel they will need financing for a facility. As I understand it this has to be in place and inspected prior to NDA approval. If they are going this way I would like them to go all in and seek funding for a Marketing Team and to take GVAX to phase III trials. Under these conditions these share price would elevate rapidly requiring less shares to be issued to finance the activitites. This type of plan would give it the respect some of the other biotech are getting and would end up with a $3+ billion market cap and much more once approved.
Just a thought, but I could see Tang purchasing the new shares issued to get to 20% of the outstanding shares. This would get the ball rolling on the climb up. His earlier shares would be given a big lift by his purchase.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.